MT2 selective melatonin receptor antagonist (Ki values are 0.46 and 56 nM for MT2 and MT1 respectively). Counteracts melatonin-mediated ERK- and Nrf2-related antioxidant potential in vivo. Centrally active.
Shin EJ et al. Melatonin attenuates memory impairment induced by Klotho gene deficiency via interactive signaling between MT2 receptor, ERK, and Nrf2-related antioxidant potential. Int J Neuropsychopharmacol18: (2015).
Read more (PubMed: 25550330) »
Juszczak M et al. The influence od melatonin receptors antagonists, luzindole and 4-phenyl-2-propionamidotetralin (4-P-PDOT), on melatonin-dependent vasopressin and adrenocorticotropic hormone (ACTH) release from the rat hypothalamo-hypophysial system. In vitro and in vivo studies. J Physiol Pharmacol65:777-84 (2014).
Read more (PubMed: 25554981) »
Wang WW et al. Abnormal response of the proliferation and differentiation of growth plate chondrocytes to melatonin in adolescent idiopathic scoliosis. Int J Mol Sci15:17100-14 (2014).
Read more (PubMed: 25257530) »